Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness

As of September 26, 2020, the novel coronavirus (SARS-CoV-2) has infected 32 million people worldwide, and killed more than 996,000 persons (Zhou F et al., 2020; The 2019 COVID pandemic was confirmed to have spread to Europe on January 31, 2020 (Grasselli et al., 2020). Since then, there have been more than 700,000 confirmed cases in Spain, with more than 31,000 deaths. As a result, Spain saw one of the most draconian Covid-19 blockades in Europe, but two months after its lift, the country is on the brink of a second wave of coronavirus infections.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research

Related Links:

Purpose of review Coronavirus disease 2019 (COVID-19) is a highly contagious and potentially lethal pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). No specific antiviral treatment is currently available. The purpose of this review is to highlight the main repurposed drug treatments with in-vitro or in-vivo efficacy against the SARS-CoV-2. Recent findings Recent clinical trials suggested remdesivir, IFN-β-1b and favipiravir have potential clinical and/or virological benefits on patients with COVID-19. Short course of stress dose of corticosteroids might be used as adjunctive tr...
Source: Current Opinion in HIV and AIDS - Category: Infectious Diseases Tags: COVID19: Edited by Zhiwei Chen and Linqui Zhang Source Type: research
AbstractThe coronavirus disease (COVID-19) is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and presents with respiratory symptoms which can be life threatening in severe cases. At the start of the pandemic, allergy, asthma, and chronic obstructive pulmonary disease (COPD) were considered as risk factors for COVID-19 as they tend to exacerbate during respiratory viral infections. Recent literature has not shown that airway allergic diseases is a high-risk factor or that it increases the severity of COVID-19. This is due to a decrease in Angiotensin-converting enzyme 2 (ACE2) gene expression in the ...
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
Summary Background Early descriptions of patients admitted to hospital during the COVID-19 pandemic showed a lower prevalence of asthma and chronic obstructive pulmonary disease (COPD) than would be expected for an acute respiratory disease like COVID-19, leading to speculation that inhaled corticosteroi ds (ICSs) might protect against infection with severe acute respiratory syndrome coronavirus 2 or the development of serious sequelae. We assessed the association between ICS and COVID-19-related death among people with COPD or asthma using linked electronic health records (EHRs) in England, UK. Me thods In this obser...
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
Jian et  al1 in a recent article refer to the immune reaction of the upper respiratory tract (URT) in patients infected by severe acute respiratory syndrome coronavirus (SARS-CoV)-2 (coronavirus disease 2019 [COVID-19] pandemic). The authors wonder about the consequences of inhaled corticosteroids (ICSs) o n immune reaction. We share the queries of Jian et al, from a practical point of view.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Correspondence Source Type: research
This article is protected by copyright. All rights reserved. PMID: 32959455 [PubMed - as supplied by publisher]
Source: The Ultrasound Review of Obstetrics and Gynecology - Category: Radiology Authors: Tags: Ultrasound Obstet Gynecol Source Type: research
ConclusionEstablishing consensus with respect to the end points to be assessed for respiratory viruses may enhance the quality of evidence in case of future pandemics. The systematic review highlighted the lacuna and methodologic deficiency in early clinical evidence and included an update on different therapeutic management guidelines. Further clinical evidence from the ongoing trials may lead to evolution of treatment guidelines with the addition of more therapeutic options.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Abstract The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), cortic...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
Background: The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a dramatic challenge for all healthcare systems worldwide. This outbreak immediately affected gastroenterologists as well as global physicians worldwide because COVID-19 can be associated with not only triggering respiratory inflammation but also gastrointestinal (GI) inflammation based on the mechanism by which SARS-CoV-2 enters cells via its receptor the angiotensin-converting enzyme 2, which is expressed on GI cells. However, the comorbidity spectrum of digestive system in patients with COVID-19 rema...
Source: Digestion - Category: Gastroenterology Source Type: research
We are living in a historic event: a novel virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China at the end of 2019 and began its global circulation. By January 24, 2020, at least 830 cases and 26 fatalities were reported across Asia and the USA [1]. 6 months later, there are more than 8 million confirmed cases of the disease associated with SARS-CoV-2, coronavirus disease 2019 (COVID-19), and over 430 000 reported deaths worldwide [2]. The pandemic has exposed cracks in healthcare systems throughout the world and identified populations vulnerable for severe disease and poorer outcome...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Editorials Source Type: research
ConclusionSixty-nine studies were included. Interestingly, MPA inhibits SARS-CoV-2 replication in-vitro. Clinical studies are needed to confirm the inhibitory effect of MPA on SARS-CoV-2 replication in-vivo. There are indications that corticosteroids and IL-6 inhibitors, like tocilizumab, can reduce mortality and prevent mechanical ventilation in patients with COVID-19. However, observational studies have contradictory results and the risk of bias is high. Thus, these results have to be confirmed in high-quality clinical trials before these drugs can be implemented as standard care. Based on the positive results of CNIs, m...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Actemra | Coronavirus | Corticosteroid Therapy | COVID-19 | Infectious Diseases | Pandemics | SARS | Spain Health